"The Duke Cancer Center in Durham, NC is a state-of-the-art patient care facility that consolidates in one convenient location almost all of the outpatient clinical care services for our patients as well as a host of amenities including a cafe, resource center, retail pharmacy and outdoor garden."

During the past decade, The Preston Robert Tisch Brain Tumor Center at Duke conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 12 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 6 clinical trials were completed. i.e. 120% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Preston Robert Tisch Brain Tumor Center at Duke" #1 sponsor was "Duke University" with 12 trials, followed by "Annick Desjardins" with 5 trials sponsored, "Bristol-Myers Squibb" with 3 trials sponsored, "Katy Peters" with 3 trials sponsored and "CASI Pharmaceuticals, Inc." with 3 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Preston Robert Tisch Brain Tumor Center at Duke" #1 collaborator was "Genentech, Inc." with 3 trials as a collaborator, "National Cancer Institute (NCI)" with 3 trials as a collaborator, "Amgen" with 2 trials as a collaborator, "Duke University" with 2 trials as a collaborator and "Eisai Inc." with 2 trials as a collaborator. Other collaborators include 20 different institutions and companies that were collaborators in the rest 27 trials.

According to Clinical.Site data, the most researched conditions in "The Preston Robert Tisch Brain Tumor Center at Duke" are "Gliosarcoma" (9 trials), "Glioblastoma" (8 trials), "Malignant Glioma" (6 trials), "Glioblastoma Multiforme" (5 trials) and "Giant Cell Glioblastoma" (3 trials). Many other conditions were trialed in "The Preston Robert Tisch Brain Tumor Center at Duke" in a lesser frequency.

Most popular intervention types in "The Preston Robert Tisch Brain Tumor Center at Duke" are "Drug" (27 trials), "Biological" (6 trials), "Radiation" (5 trials), "Behavioral" (4 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Temozolomide" (7 trials), "Avastin" (3 trials), "Bevacizumab" (3 trials), "Nivolumab" (3 trials) and "Irinotecan" (2 trials). Other intervention names were less common.

The vast majority of trials in "The Preston Robert Tisch Brain Tumor Center at Duke" are 36 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "The Preston Robert Tisch Brain Tumor Center at Duke". 3 are not yet recruiting, undefined are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 19 completed trials in The Preston Robert Tisch Brain Tumor Center at Duke, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in The Preston Robert Tisch Brain Tumor Center at Duke, 8 "Phase 1" clinical trials were conducted, 17 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 4 trials that are defined as “Not Applicable".